comparemela.com

Latest Breaking News On - Biotech and pharma - Page 3 : comparemela.com

Prospects Look Better for Sarepta Gene Therapy, Sending the Stock Up Again

Investors looking for signs the FDA will let more patients use Sarepta Therapeutics’ Duchenne muscular dystrophy treatment got exactly that.

Doug ingramJosh nathan kazisPeter marksDrug administrationSarepta therapeuticsBiologics evaluationArticle normalBiotechnology servicesHealthcare life sciencesBiological therapyHealthcare provisionRegulation government policyNew products servicesResearch developmentCorporate industrial newsProducts services

Lilly Stock s Upside Prompts Morgan Stanley to Ask if It Can Reach $1 Trillion

Morgan Stanley analyst Terence Flynn increases his price target on shares of the drugmaker to $950 from $805.

Terence flynnAngela palumboEli lillyDaniel acker bloombergMorgan stanleyAdvanced micro devicesDow jones marketWall streetArticle normalAgricultural machineryHealthcare life sciencesIndustrial electronicsIndustrial goodsFinancial performanceAnalysts amp 39 comments recommendationsShare price movement disruptions

West Pharmaceutical Stock Tumbles on Weak 2024 Outlook

The contract manufacturer West Pharmaceutical Services laid out a grim outlook for 2024 sales and earnings, sending West stock on a dive.

Eric greenQuintin laiJosh nathan kazisWilliam blairMatt larewDavid windleyWest pharmaceutical servicesArticle normalMedical equipment suppliesHealthcare life sciencesFinancial performanceSales figuresCorporate industrial newsContent typesFactiva filtersC amp ampe industry news filter

Biogen Stock Drops as Earnings and Guidance Disappoint

Biogen’s new CEO, Christopher Viehbacher, said the company is well positioned to return to sustainable growth.

Michael yeeJosh nathan kazisChristopher viehbacherVanessa leroy bloombergDrug administrationWall streetSage therapeuticsArticle normalOil and gas upstream operationsBiotechnology servicesHealthcare life sciencesOil and gas extractionFossil fuelsOil and gasFinancial performanceShare price movement disruptions

JetBlue, Arm, ZoomInfo, Tripadvisor, Arista, Cadence Design, Coca-Cola, and More Movers

Carl Icahn discloses a 9.9% stake in JetBlue, Arm shares trade lower after surging 29% on Monday, and ZoomInfo’s fourth-quarter earnings and revenue beat.

Spencer platt gettyNew york stock exchangeYork stock exchangeNew york stockGetty imagesArticle normalAgricultural machineryPortable power toolsRetail wholesaleFood retailingSpecialty retailingPassenger airlinesCommercial bankingAir transportBusiness consumer servicesBanking credit

vimarsana © 2020. All Rights Reserved.